Structured JSON API for this factor page: https://sharemaestro.com/factors/api/tickers/94f6d8a8-5841-4948-951d-f63d0f95de95/

HRMY

Harmony Biosciences Holdings
Chart
36.84 USD
Latest Week 2026-07-10
HealthcareBiotechnologyMID
Snapshot 2026-07-12 · 0.9w · Fresh
0.96
OS Score
87.0%
Value
98.0%
Quality
66.0%
Momentum
5/9
F-Score
0.923
QV
StrategiesValueQualityMomentumCompositeInteractionsFactor AnalysisTrendsFundamentals
Strategy Eligibility
5 of 23 passing
★
OS Composite
OS 0.960
↗
Trending Value
✗
◆
Quality × Value
QV 0.923
🏛
Cornerstone Value
✗
🌿
Cornerstone Growth
✗
💎
Deep Value
✗
◇
VC2 Cheapest
✗
📐
EBITDA/EV
13.3%
◐
Veiled Value
✗
▣
Piotroski Bargains
✗
🔬
Quality Compounders
ROE 16%
📈
Consistent Earners
✗
🌱
GARP
Rev +21%
🔄
Shareholder Yield
✗
💰
High Yield
✗
🚀
Momentum Leaders
✗
◉
Market Leaders
✗
◎
Tiny Titans
✗
🔍
Small Cap Value
✗
🛡
Low Volatility
✗
🏷
Sector Cheapest
✗
🧠
Capital Allocators
✗
⚡
Risk-Adj Momentum
✗
V
Value Analysis
Cheapness relative to fundamentals
87.0%ile
P/E
14.6×
P/S
2.4×
P/B
2.3×
E/P
0.1189
FCF Yield
0.196
EBITDA/EV
0.133
SH Yield
-0.003
Relative Strength Across Value Dimensions
Multiples & Yields — Decomposition
VC1 (5-Factor)
21.00000000
/100 — 1=cheapest
VC2 (Trending Value)
31.00000000
/100
VC3 (Buyback)
29.00000000
/100
FCF yield of 19.6% is strong — the business generates significant free cash relative to price.
Q
Quality Analysis
Profitability, efficiency, balance sheet & earnings quality
98.0%ile
ROE
0.160
ROA
0.114
Net Margin
0.162
Op Margin
0.231
GPA
0.541
D/E
0.40
Current
3.58
F-Score
5/9
Quality Radar — Relative Strength
Profitability & Leverage Breakdown
Rev Growth
0.207
Earn Growth
-0.047
Stability
0.378
lower=better
Accruals
-0.154
lower=better
5yr Consist
No
Conservative balance sheet with D/E of 0.40.
M
Momentum & Risk
Price trend, volatility regime, risk-adjusted returns
66.0%ile
6M Return
-4.4%
12M Return
8.4%
12-1 Mom
1.4%
Risk-Adj
0.03
Vol 252d
45.1%
Vol 60d
96.3%
↑ Expanding
Max DD 12M
-34.5%
Return Comparison — 6M / 12M / 12-1
Volatility Regime — 60d vs 252d
Near-term vol (96%) is expanding vs long-term (45%) — risk is increasing.
OS
Composite & Factor Heatmap
All factors at a glance
0.96
Pillar Balance — Value / Quality / Momentum
Factor Heatmap — green=strong, red=weak
▦
Sector Context
Healthcare · 500 peers
Sector Value %ile
92.6%
Sector Quality %ile
99.4%
P/E z-score
-0.26
P/B z-score
-0.22
Sector Avg OS
63.1%
Ticker vs Sector Averages
Relative Valuation Z-Score
Top Sector Peers (By OS)
SymbolNameOSValueQualityMomentum
FBIO Fortress Biotech Inc 99.0% 98.0% 85.0% 90.0%
FBIOP Fortress Biotech Inc Pref Series A 99.0% 98.0% 83.0% 95.0%
IRWD Ironwood Pharmaceuticals Inc 99.0% 90.0% 91.0% 99.0%
TBPH Theravance Biopharma Inc 99.0% 90.0% 99.0% 88.0%
RIGL Rigel Pharmaceuticals Inc 99.0% 89.0% 93.0% 94.0%
INVA Innoviva Inc 98.0% 94.0% 94.0% 75.0%
NUTX Nutex Health Inc 98.0% 89.0% 98.0% 86.0%
CGEN Compugen 98.0% 89.0% 96.0% 85.0%
Factor Interactions
Value + Quality Intersection
Top-tier on both cheapness (87th) and quality (98th) — the O'Shaughnessy sweet spot, historically the strongest long-term combination.
Growth at Reasonable Price
Revenue growing 21% with P/E of 15×. Growth isn't fully priced in.
Volatility Expanding
60-day vol (96%) significantly exceeds 252-day (45%). Near-term risk is elevated.
⚖
Factor Analysis
Comprehensive factor intelligence — strengths, weaknesses & cross-factor profile
Value
B
70.6% avg (7 factors)
Quality
A
80.5% avg (8 factors)
Momentum
D
33.9% avg (4 factors)
Risk
D
41.6% avg (1 factors)
This stock sits in the O'Shaughnessy sweet spot — cheap AND high quality. Historically, this combination has generated the strongest long-term returns. Momentum is weak, suggesting the market isn't yet buying this thesis. Patience required. Elevated risk profile — position sizing should reflect the higher volatility.
▲ Top Strengths — highest scoring factors
▼ Key Weaknesses — lowest scoring factors
Score Trends6 snapshots
Factor Persistence6 snapshots
FactorCurrentStreakTrendSpark
OS Composite0.960—6—
Value %ile0.870—6—
Quality %ile0.980—6—
Momentum %ile0.660—0—
F-Score5.000—0—
Confidence0.951—6—
Volatility0.451—6—
Value Lens2021-07-13 → 2026-07-12
P/E Ratio
Earnings Yield
Value FactorsCheapness relative to fundamentals — lower multiples = cheaper
P/E Ratio
14.65
Earnings Yield (E/P)
0.1189
Price / Sales
2.37
Price / Book
2.34
Price / Cash Flow
6.24
FCF Yield
19.6%
EBITDA / EV
13.3%
Sales Yield (1/P·S)
0.5138
Shareholder Yield
Div + net buyback / mktcap
-0.3%
Quality FactorsProfitability, efficiency, and balance sheet strength
Return on Equity
16.0%
Return on Assets
11.4%
Net Margin
16.2%
Operating Margin
23.1%
Gross Profit / Assets
Novy-Marx GPA
54.1%
Debt / Equity
0.40
Current Ratio
3.58
Accruals Ratio
(NI-OCF)/Assets — lower=better
-0.154
External Financing
Net issuance — lower=better
0.005
MomentumPrice trend strength over different horizons
6M Return
-4.4%
12M Return
8.4%
12-1 Momentum
Jegadeesh-Titman (skip recent month)
1.4%
Risk-Adjusted Momentum
Mom 12-1 ÷ Vol
0.03
Growth & StabilityEarnings trajectory, consistency, and capital allocation
Revenue Growth (YoY)
20.7%
Earnings Growth (YoY)
-4.7%
Earnings Stability (CV)
Lower = more stable
0.378
5yr Consistent
EPS up every year for 5 years
No
Piotroski F-Score
5
Buyback Yield
-0.3%
O'Shaughnessy CompositesValue Composites (WWOWS 4th Ed) — 1=cheapest, 100=most expensive
VC1 (5-factor)
P/E+P/S+P/B+P/CF+EBITDA/EV
21
VC2 (6-factor)
VC1 + Shareholder Yield — used for Trending Value
31
VC3 (6-factor)
VC1 + Buyback Yield — no dividend preference
29
Capital Allocation & AlphaAlpha within factors — quality of management decisions
Veiled Value
Expensive by P/B, cheap by everything else
No
Market Leader
Above-avg mcap+revenue, non-utility
No
All Stocks Universe
Market cap > $200M
Yes
Tiny Titan
Micro-cap, low P/S, positive momentum
No
Quarterly Fundamentals
Revenue
Net Income
FCF
Net Margin
Show all
Op Income
OCF
CapEx
Equity
Annual Fundamentals
Revenue
Net Income
FCF
Net Margin
Show all
Op Income
OCF
CapEx
Equity